Skip to content

Sunday, November 17, 2024

Latest:

Why comprehensive metrics matter in patient outcome studies
Raising awareness about pancreatic cancer: A message from Dr. William E. Fisher
Brain stars hold our memories
Adult allergies: Q&A with Dr. David Corry
Quitting smoking: tips for lung cancer awareness month

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

PI3K inhibitor

Targeting MAPK4 may offer a new therapeutic opportunity for TNBC

January 27, 2022 AKT, cancer therapy, MAPK4, PI3K, PI3K inhibitor, Research, triple-negative breast cancer

MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.

From the Labs: Image of the Month

From the Labs: Aging signs.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951